Company intelligence / Profile preview
SymbioCellTech
Salt Lake City, Utah, United States
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Preclinical studies have shown promising results for Neo-Islets in treating Type 1 diabetes. A clinical trial in diabetic pet dogs yielded up to 50% reduction in insulin needs and ~100mg/dL reduction in blood glucose levels, sustained for over 15 months.
- Therapeutic areas
- EndocrinologyCardiovascularNephrology
- Modalities
- Cell therapyStem cell therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Virbac (veterinary pharmaceutical group)
Beyond the preview
Go deeper on SymbioCellTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SymbioCellTech.